Trial Profile

A Phase 2a Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of CAD-1883 Oral Treatment in Adults With Essential Tremor

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rimtuzalcap (Primary)
Indications Essential tremor
Focus Adverse reactions
Acronyms Cadence-1
Sponsors Cadent Therapeutics

Most Recent Events

06 Feb 2020 According to an Cadent Therapeutics media release, this study will be highlighted in a poster presentation at the 3rd Pan American Parkinson's Disease and Movement Disorders Congress from February 14-16, 2020 at the InterContinental Miami.
22 Oct 2019 Status changed from recruiting to completed.
17 Oct 2019 Results presented in the Cadent Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com